Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
Lixisenatide
A once-daily GLP-1 receptor agonist for glycaemic control in type 2 diabetes — shorter-acting than the weekly agents that dominate headlines.
Exenatide
The first GLP-1 receptor agonist — born from Gila-monster venom peptide biology — with formulations ranging from twice-daily to weekly injection.
How far human research has progressed
Lixisenatide
Established GLP-1 medicineExenatide
Established GLP-1 medicine familyClaim-specific benefit evidence
A human exposure study or trial registration does not establish that the claimed benefit occurs.
Lixisenatide
Not separately assessed; see the full profile.Exenatide
Not separately assessed; see the full profile.Human research context
Lixisenatide
Established GLP-1 medicineExenatide
Established GLP-1 medicine familyHuman efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
Lixisenatide
Exenatide
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
Lixisenatide
Exenatide
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
Lixisenatide
Exenatide
Regulatory status (legal position, not proof it works)
Lixisenatide
Named regulators: FDA (US)
FDA-approved (Adlyxin) as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes; also marketed in some regions as Lyxumia.
Exenatide
Named regulators: FDA (US)
FDA-approved (Byetta; the Bydureon family) as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. Different formulations carry different dosing schedules and label details.
Common claims
Lixisenatide
- · Improves glycaemic control in type 2 diabetes
Exenatide
- · Improves blood-glucose control in type 2 diabetes
- · Modest weight reduction in treated patients
How settled our evidence rating is
Lixisenatide
Exenatide
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
Lixisenatide
No established human cancer signal within approved use.Exenatide
Rodent thyroid C-cell tumour findings are a labelled mechanistic class consideration for the extended-release formulation; a causal human risk is not established.What this adds up to, in plain English
Lixisenatide
Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.Exenatide
Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.A comparison is not a recommendation